CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study is testing a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The main goal is to find the safest dose and understand side effects…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis study tests whether adding chemotherapy to an immunotherapy drug (atezolizumab) works better than immunotherapy alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). About 240 adults with cancer that hasn't spread far wi…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New combo therapy aims to boost stomach cancer treatment before surgery
Disease control OngoingThis study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery can safely treat stomach cancer. About 32 adults with resectable gastric or gastroesophageal junction cancer will receive this combination. The goa…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Immunotherapy combo shows promise in esophageal cancer fight
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can help shrink tumors in people with esophageal or gastroesophageal junction cancer before surgery. About 278 adults with stage II to IVA cancer will be e…
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Immunotherapy plus chemoradiation shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested a combination of the immunotherapy drug pembrolizumab with chemotherapy and radiation in 16 people whose gastroesophageal cancer could not be removed by surgery. The goal was to see if the treatment could shrink or eliminate the cancer. The study is …
Matched conditions: CLINICAL STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC